Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Laboratory for Molecular Medicine, |
RCV000038481 | SCV000062159 | likely benign | not specified | 2017-01-25 | criteria provided, single submitter | clinical testing | p.Asp612Asn in exon 08 of TECTA: This variant is not expected to have clinical s ignificance because it has been identified in 0.4% (42/10348) of African chromos omes by the Exome Aggregation Consortium (ExAC, http://exac.broadinstitute.org; dbSNP rs143730090). |
Eurofins Ntd Llc |
RCV000038481 | SCV000332526 | benign | not specified | 2015-07-09 | criteria provided, single submitter | clinical testing | |
Gene |
RCV001582512 | SCV001813255 | uncertain significance | not provided | 2021-05-25 | criteria provided, single submitter | clinical testing | In silico analysis supports that this missense variant does not alter protein structure/function; Has not been previously published as pathogenic or benign to our knowledge |
Labcorp Genetics |
RCV001582512 | SCV002144515 | likely benign | not provided | 2023-12-28 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004018875 | SCV004963831 | uncertain significance | Inborn genetic diseases | 2024-01-30 | criteria provided, single submitter | clinical testing | The c.1834G>A (p.D612N) alteration is located in exon 8 (coding exon 8) of the TECTA gene. This alteration results from a G to A substitution at nucleotide position 1834, causing the aspartic acid (D) at amino acid position 612 to be replaced by an asparagine (N). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |